Announcement regarding the FDA approval of the clinical trial for pharmaceuticals by our subsidiary in the USA.
Announcement of Resolutions of the Twentieth Meeting of the Fourth Supervisory Board.
CITIC Securities Co., Ltd.'s verification opinion on Gan & Lee Pharmaceuticals Co., Ltd.'s continuing use of idle raised funds for cash management.
Announcement of resolutions of the 21st meeting of the fourth board of directors
Announcement regarding the continued use of idle funds raised for cash management.
Announcement on the Progress of Using Idle Funds for Cash Management
Announcement on the Use of Idle Raised Funds for Cash Management and Redemption upon Maturity.
Ganli Pharmaceutical Co., Ltd. Capital Inspection Report
Announcement of Resolutions of the 19th Meeting of the Fourth Board of Directors
Announcement of Resolutions of the 18th Meeting of the Fourth Board of Supervisors
Announcement of Resolutions of the 19th Meeting of the Fourth Board of Supervisors
CITIC Securities Co., Ltd.'s 2023 Continued Supervision Report on Ganli Pharmaceutical Co., Ltd.
CITIC Securities Co., Ltd. on the inspection results of Ganli Pharmaceutical Co., Ltd.'s 2023 continuous supervision work site inspection results and reminders to the company
CITIC Securities Co., Ltd. site inspection report on Gan Li Pharmaceutical Co., Ltd.'s 2023 continuous supervision work
Ganli Pharmaceutical Co., Ltd. Audit Report
Verification report on the storage and use of raised funds
Announcement of Resolutions of the 18th Meeting of the Fourth Board of Directors
Announcement on renewing the Company's 2024 Audit Institution
Articles of Association of Ganli Pharmaceutical Co., Ltd. (April 2024)
Special instructions on the use of capital by controlling shareholders and other related parties
No Data